IPSEN (OTCMKTS:IPSEY) Shares Gap Down – What’s Next?

IPSEN (OTCMKTS:IPSEY) shares gapped down before the market opened on Tuesday . The stock had previously closed at $46.75, but opened at $43.61. IPSEN shares last traded at $43.61, with a volume of 300 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on IPSEY shares. HC Wainwright started coverage on shares of IPSEN in a research report on Friday, June 5th. They set a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Finally, Zacks Research raised IPSEN to a “hold” rating in a research report on Friday, May 29th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, IPSEN has a consensus rating of “Hold”.

IPSEN Trading Down 6.7%

The company’s 50-day moving average is $47.94 and its two-hundred day moving average is $43.13.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).